PULMONARY FUNCTION IN RHEUMATOID ARTHRITS: A CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.22159/ijcpr.2024v16i2.4057Keywords:
Pulmonary function, Spirometry, Rheumatoid arthritis, Extraarticular manifestations, Disease activity, MethotrexateAbstract
Objective: Rheumatoid arthritis (RA) is an autoimmune disease with many extraarticular manifestations. Pulmonary involvement is seen in 60-80% cases with and without symptoms. This research studies the pattern of PFT (Pulmonary Function Test) in RA and find the correlation between PFT and Disease activity. Secondary objectives were to evaluate the effect of use of Methotrexate (MTx) on disease activity and PFT.
Methods: An outpatient-based descriptive cross-sectional study was conducted in General Medicine department at a tertiary centre among 100 eligible patients. Disease activity score was recorded using DAS-28 (Disease Activity Score-28) and CDAI (Clinical Disease Activity Index). Patients underwent PFT by Spirometry thereafter.
Results: 45 % patients had restrictive pattern and 55% had normal PFT. None had an obstructive pattern. The mean FVC (Forced Vital Capacity), FEV1 (Forced Expiratory Volume in the first second), FEV1/FVC ratio, PEFR (Peak Expiratory Flow Rate) and FEF 25-75% (Forced mid expiratory flow) were 78.83±14.37, 79.24±16.96, 103.56±11.03, 71.73±22.39 and 76.56±23.72 respectively. Both FVC and FEV1 were found to be significantly associated with age, disease duration, CDAI score, MTx dose and duration (P<0.05). Age, ESR(erythrocyte sedimentation rate) and MTx dose were significantly associated with FEV1/FVC ratio (P<0.05). Age, duration of disease, ESR. MTx dose and duration were significantly associated with PEFR (P<0.05). Lastly age, CDAI score, MTx dose and duration were significantly associated with FEF 25-75% (P<0.05).
Conclusion: Restrictive pattern (45%) was the most common defect on PFT among RA patients. Severity of lung disease depends on age, MTx dose, disease activity (ESR, CDAI), duration of disease and MTx duration.
Downloads
References
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1316-22. doi: 10.1136/annrheumdis-2013-204627, PMID 24550173.
Handa R, Rao Ur, Handa R, Rao UR, Lewis JF, Rambhad G, Shiff S, Ghia CJ. Literature review of rheumatoid arthritis in India. Int J Rheum Dis. 2016;19(5):440-51. doi: 10.1111/1756-185X.12621, PMID 26171649.
Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clin Chest Med. 2019;40(3):545-60. doi: 10.1016/j.ccm.2019.05.003, PMID 31376890.
Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score with ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res. 2011;63Suppl 11:S14-36. doi: 10.1002/acr.20621, PMID 22588741.
Lopez Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;62014(6):CD000957. doi: 10.1002/14651858.CD000957.pub2, PMID 24916606.
Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med (Lausanne). 2019;6(6):238. doi: 10.3389/fmed.2019.00238, PMID 31709258.
Ponce MC, Sharma S. Pulmonary function tests. StatPearls. 2022.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805, PMID 16055882.
Prisco L, Moll M, Wang J, Hobbs BD, Huang W, Martin LW. Relationship between rheumatoid arthritis and pulmonary function measures on spirometry in the UK Biobank. Arthritis Rheumatol. 2021 Nov;73(11):1994-2002. doi: 10.1002/art.41791, PMID 33982900.
Zayeni H, Haji-Abbasi A, Foumani SA, Tohidi M, Masooleh IS, Parsa BG. Pulmonary involvement in rheumatoid arthritis: a cross-sectional study in Iran. Lung India. 2016 Jan-Feb;33(1):49-52. doi: 10.4103/0970-2113.173062, PMID 26933307.
Pappas DA, Giles JT, Connors G, Lechtzin N, Bathon JM, Danoff SK. Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther. 2010;12(3):R104. doi: 10.1186/ar3037, PMID 20507627.
Al-Assadi T, Al-Shemery A, Salman S. Correlation of lung function with disease activity rheumatoid arthritis. Oman Med J. 2009;24(2):84-8. doi: 10.5001/omj.2009.20, PMID 22334850.
Avnon LS, Manzur F, Bolotin A, Heimer D, Flusser D, Buskila D. Pulmonary functions testing in patients with rheumatoid arthritis. Isr Med Assoc J. 2009 Feb;11(2):83-7. PMID 19432035.
Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015;24(135):1-16. doi: 10.1183/09059180.00008014, PMID 25726549.
Martinez Pitre PJ, Sabbula BR, Cascella M. Restrictive lung disease. StatPearls. 2022.
Li L, Liu R, Zhang Y, Zhou J, Li Y, Xu Y. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2020 May;39(5):1457-70. doi: 10.1007/s10067-019-04846-1, PMID 31858341.
Kronzer VL, Huang W, Dellaripa PF, Huang S, Feathers V, Lu B. Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease. J Rheumatol. 2021 May;48(5):656-63. doi: 10.3899/jrheum.200863, PMID 33191286.
Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol. 2019 Sep;71(9):1472-82. doi: 10.1002/art.40904, PMID 30951251.
Perez Dorame R, Mejia M, Mateos Toledo H, Rojas Serrano J. Rheumatoid arthritis-associated interstitial lung disease: lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Reumatol Clin. 2015;11(1):12-6. doi: 10.1016/j.reuma.2014.02.007, PMID 24913966.
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803-12. doi: 10.1002/art.38322, PMID 24757133.
Juge PA, Lee JS, Lau J, Kawano Dourado L, Rojas Serrano J, Sebastiani M. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021 Feb 11;57(2):2000337. doi: 10.1183/13993003.00337-2020, PMID 32646919.
Published
How to Cite
Issue
Section
Copyright (c) 2024 AISHWARYA MALODE, R N YADAV, GIRDHAR GOPAL GOYAL, GUNJA JAIN, AJAY MATHUR, LAXMIKANT GOYAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
